Abstract
Painful diabetic neuropathy (PDN) is found in about 16 % of diabetes patients and is not optimally managed in that 40 % of individuals with PDN are untreated [1]. Such gaps in care produce patient dissatisfaction and negatively impact quality of life [2]. Since efficacious, evidence-based treatments are available for PDN [3], it becomes important to understand why treatment is not offered to patients. In part, this lack of treatment may arise from failure to make the diagnosis of PDN. This chapter aims to present a discussion concerning the diagnosis of PDN that may allow better treatment of patients.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Daousi C, MacFarlane IA, Woodward A, Nurmikko TJ, Bundred PE, Benbow SJ. Chronic painful peripheral neuropathy in an urban community: a controlled comparison of people with and without diabetes. Diabet Med. 2004;21(9):976–82.
Gore M, Brandenburg N, Hoffman D, Tai K. Burden of illness in painful diabetic peripheral neuropathy: the patients’ perspectives. J Pain. 2006;7(12):892–900.
Bril V, England J, Franklin GM, Backonja M, Cohen J, Del Toro D, et al. Evidence-based guideline: treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology. 2011;76(20):1758–65.
Vileikyte L, Gonzalez JS, Garrow AP, Stickings D, Waterman C, Ulbrecht JS, et al. Predictors of depressive symptoms in persons with diabetic peripheral neuropathy: a longitudinal study. Diabetologia. 2009;52(7):1265–73.
Bouhassira D, Attal N. Diagnosis and assessment of neuropathic pain: the saga of clinical tools. Pain. 2011;152(3 Suppl):S74–83.
Attal N, Bouhassira D, Baron R, Dostrovsky J, Dworkin RH, Finnerup N, et al. Assessing symptom profiles in neuropathic pain clinical trials: can it improve outcome? Eur J Pain. 2011; 15(5):441–3.
Hartemann A, Attal N, Bouhassira D, Dumont I, Gin H, Jeanne S, et al. Painful diabetic neuropathy: diagnosis and management. Diabete Metab. 2011;37(5):377–88.
Zelman DC, Gore M, Dukes E, Tai K-S, Brandenburg N. Validation of a modified version of the brief pain inventory for painful diabetic peripheral neuropathy. J Pain Symptom Manage. 2005;29(4):401–10.
Krause SJ, Backonja M-M. Development of a neuropathic pain questionnaire. Clin J Pain. 2003;19(5):306–14.
Backonja M-M, Krause SJ. Neuropathic pain questionnaire—short form. Clin J Pain. 2003;19(5):315–6.
Bouhassira D, Attal N, Fermanian J, Alchaar H, Gautron M, Masquelier E, et al. Development and validation of the Neuropathic Pain Symptom Inventory. Pain. 2004;108(3):248–57.
Galer BS, Jensen MP. Development and preliminary validation of a pain measure specific to neuropathic pain: the Neuropathic Pain Scale. Neurology. 1997;48(2):332–8.
Bouhassira D, Attal N. All in one: is it possible to assess all dimensions of any pain with a simple questionnaire? Pain. 2009;144(1–2):7–8.
Perkins BA, Olaleye D, Zinman B, Bril V. Simple screening tests for peripheral neuropathy in the diabetes clinic. Diabetes Care. 2001;24(2):250–6.
Bril V, Tomioka S, Buchanan RA, Perkins BA, mTCNS Study Group. Reliability and validity of the modified Toronto Clinical Neuropathy Score in diabetic sensorimotor polyneuropathy. Diabet Med. 2009;26(3):240–6.
Zinman LH, Bril V, Perkins BA. Cooling detection thresholds in the assessment of diabetic sensory polyneuropathy: comparison of CASE IV and Medoc instruments. Diabetes Care. 2004;27(7):1674–9.
Bril V, Kojic J, Clark K. Comparison of a neurothesiometer and vibratron in measuring vibration perception thresholds and relationship to nerve conduction studies. Diabetes Care. 1997;20(9):1360–2.
Dyck PJ, Bushek W, Spring EM, Karnes JL, Litchy WJ, O’Brien PC, et al. Vibratory and Âcooling detection thresholds compared with other tests in diagnosing and staging diabetic Âneuropathy. Diabetes Care. 1987;10(4):432–40.
Gerr F, Letz R, Hershman D, Farraye J, Simpson D. Comparison of vibrotactile thresholds with physical examination and electrophysiological assessment. Muscle Nerve. 1991;14(11): 1059–66.
Gelber DA, Pfeifer MA, Broadstone VL, Munster EW, Peterson M, Arezzo JC, et al. Components of variance for vibratory and thermal threshold testing in normal and diabetic subjects. J Diabetes Complications. 1995;9(3):170–6.
Krishnan STM, Rayman G. The LDIflare: a novel test of C-fiber function demonstrates early neuropathy in type 2 diabetes. Diabetes Care. 2004;27(12):2930–5.
Krishnan STM, Quattrini C, Jeziorska M, Malik RA, Rayman G. Abnormal LDIflare but normal quantitative sensory testing and dermal nerve fiber density in patients with painful diabetic neuropathy. Diabetes Care. 2009;32(3):451–5.
Green AQ, Krishnan STM, Rayman G. C-fiber function assessed by the laser doppler imager flare technique and acetylcholine iontophoresis. Muscle Nerve. 2009;40(6):985–91.
Lauria G, Cornblath DR, Johansson O, McArthur JC, Mellgren SI, Nolano M, et al. EFNS guidelines on the use of skin biopsy in the diagnosis of peripheral neuropathy. Eur J Neurol. 2005;12(10):747–58.
England JD, Kinsella LJ, Cohen JA, Asbury AK, Szigeti K, Lupski JR, et al. Practice parameter: evaluation of distal symmetric polyneuropathy: role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review). Report of the American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and American Academy of Physical Medicine and Rehabilitation. Neurology. 2009;72(2):177–84.
Kennedy WR, Wendelschafer-Crabb G, Johnson T. Quantification of epidermal nerves in Âdiabetic neuropathy. Neurology. 1996;47(4):1042–8.
Lauria G, Holland N, Hauer P, Cornblath DR, Griffin JW, McArthur JC. Epidermal innervation: changes with aging, topographic location, and in sensory neuropathy. J Neurol Sci. 1999; 164(2):172–8.
Umapathi T, Tan WL, Loke SC, Soon PC, Tavintharan S, Tavintharan S, Chan YH. Intraepidermal nerve fiber density as a marker of early diabetic neuropathy. Muscle Nerve. 2007;35(5):591–8.
Tan IL, Polydefkis MJ, Ebenezer GJ, Hauer P, McArthur JC. Peripheral nerve toxic effects of nitrofurantoin. Arch Neurol. 2012;69(2):265–8.
Malik RA, Kallinikos P, Abbott CA, van Schie CH, Morgan P, Efron N, et al. Corneal confocal microscopy: a non-invasive surrogate of nerve fibre damage and repair in diabetic patients. Diabetologia. 2003;46(5):683–8.
Hertz P, Bril V, Orszag A, Ahmed A, Ng E, Nwe P, et al. Reproducibility of in vivo corneal confocal microscopy as a novel screening test for early diabetic sensorimotor polyneuropathy. Diabet Med. 2011;28(10):1253–60.
Attal N, Cruccu G, Baron R, Haanpaa M, Hansson P, Jensen TS, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17(9): 1113–88.
Dworkin RH, O’Connor AB, Audette J, Baron R, Gourlay GK, Haanpää ML, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc. 2010;85(3 Suppl):S3–14.
Kieburtz K, Simpson D, Yiannoutsos C, Max MB, Hall CD, Ellis RJ, et al. A randomized trial of amitriptyline and mexiletine for painful neuropathy in HIV infection. AIDS Clinical Trial Group 242 Protocol Team. Neurology. 1998;51(6):1682–8.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this chapter
Cite this chapter
Bril, V., Perkins, B.A. (2013). Diagnosis of Painful Diabetic Neuropathy. In: Lawson, E., Backonja, M. (eds) Painful Diabetic Polyneuropathy. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-6299-6_3
Download citation
DOI: https://doi.org/10.1007/978-1-4614-6299-6_3
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-6298-9
Online ISBN: 978-1-4614-6299-6
eBook Packages: MedicineMedicine (R0)